Preterm premature rupture of membranes (PPROM) occurs in 3 to 4.5% of pregnancies. It accounts for one-third of all preterm births and is associated with significant infant morbidity and mortality.\textsuperscript{1,2} Compared with singletons, twins have both a higher rate of PPROM and a shorter latency from the time of PPROM to delivery, suggesting the greater impact of PPROM on outcomes in twins.\textsuperscript{3,4}

Preivable PPROM, defined as spontaneous ROM occurring between 13 and 23 6/7 weeks’ gestational age is rare, occurring in 1.37% of twin and 0.52% of singleton pregnancies.\textsuperscript{4} A retrospective cohort study reported that 43% of twins born following PROM at < 26 weeks survive, but 83% of survivors had significant neonatal morbidity.\textsuperscript{5} This is in contrast to singletons, where though overall survival is comparable,
frequencies of long-term neonatal morbidity appear lower, 52 to 73%.

In singletons with PPROM occurring between 24 and 34 weeks’ gestational age, antenatal corticosteroids, neuroprotective magnesium sulfate (24–32 weeks’ gestation), and prophylactic antibiotics are associated with improved neonatal outcomes.\textsuperscript{9,10} In addition, mothers carrying singleton gestations complicated by PPROM between 24 and 32 weeks’ gestational age are typically offered prophylactic antibiotics (sometimes referred to as “latency” antibiotics), as this treatment increases the time between ROM and delivery by a median of 4 days and reduces perinatal morbidity.\textsuperscript{10} A recent guideline published by the American Congress of Obstetrics and Gynecology noted that there was inadequate data on the previable period to recommend the use of antibiotic to increase latency, but stated that it should be considered based on level 2B–2C data.\textsuperscript{11} However, there is wide variation in the use of prophylactic antibiotics in the setting of the PPROM \textless 24 weeks’ gestation, and particularly among twins with PPROM \textless 24 weeks’ gestation.

The primary objective of this study was to examine the association between prophylactic antibiotic use at the time of previable PROM and latency time from PPROM to delivery in twins.

\textbf{Material and Methods}

This is a retrospective cohort study conducted at a single-tertiary care referral center. Using the International Classification of Diseases codes of PPROM, PROM, and spontaneous abortion (634.0, 634.1, 634.8, 634.9, 635.0, 635.1, 635.2, 635.7, 635.9, 637.0, 637.1, 637.7, 637.8, and 637.9) all women from 2000 to 2015 with PPROM and twin gestation between 14 0/7 weeks and 23 6/7 weeks gestation were identified from the University of North Carolina (UNC) Women’s Hospital delivery log and from billing records. Women were included if they had ruptured membranes without labor at between 14 0/7 and 22 6/7 weeks, carried multiple gestations, and elected expectant management of the pregnancy after PPROM. ROM was defined as documentation in the medical record of ROM confirmed by evaluation of history, physical examination, nitrazine or fern test, or intra-amniotic fluid injection of indigo carmine dye.\textsuperscript{12} The distinction between PPROM of twin A versus twin B was made at the time of initial evaluation for PPROM based on which twin was presenting on ultrasound as documented in the admission note. For the purposes of this study, twin A was the presenting twin and twin B was the nonpresenting twin at the time of PPROM evaluation. Women who elected immediate delivery (via either induction of labor or dilation and evacuation), who had a contraindication for expectant management (e.g., suspected chorioamnionitis, active maternal hemorrhage), presented in labor (regular uterine contractions with progressive cervical change) or who had iatrogenic PPROM due to amniocentesis, chorionic villus sampling, or laser procedure for twin–twin transfusion treatment were excluded. Women who delivered both fetuses within 24 hours of PPROM or were missing delivery data were also excluded. We defined prophylactic antibiotics as antibiotics given specifically for the purpose of prolonging latency as documented in the medical record and that were started within 24 hours of membrane rupture. Prophylactic antibiotics were given at the primary clinician’s discretion; type and dose of antibiotic choice, as well as timing and length of administration, was recorded. The study was reviewed and approved by the Institutional Review Board at the UNC at Chapel Hill.

We compared pregnancy outcomes among those with and without exposure to prophylactic antibiotics for PPROM. The primary outcome was duration from ROM to delivery of the twin A. Secondary outcomes included duration from ROM to delivery of the twin B, perinatal mortality (fetal or neonatal death before 28 days after delivery), neonatal morbidity (among survivors to neonatal intensive care unit discharge)

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{study_population.png}
\caption{Study population.}
\end{figure}
composite of sepsis, bronchopulmonary dysplasia, pulmonary hypoplasia, necrotizing enterocolitis, and grade 3 or 4 intraventricular hemorrhage), and maternal morbidity (composite of intensive care unit admission, blood transfusion, sepsis, endometritis, hysterectomy, pulmonary embolism, deep vein thrombosis, wound infection, and readmission).

Bivariate analysis was performed with chi-square, Fischer exact test, or Mann–Whitney U test as appropriate. A log-rank test was used to analyze the effect of antibiotic exposure on latency to delivery for both twin A and separately for twin B, and a Cox hazard proportional ratio for antibiotic use and latency was calculated. Significance was set at $p < 0.05$. Statistical analysis was performed using Stata software (version 14.0; Stata Corporation, College Station, TX).

## Results

A total of 284 women were diagnosed with PPROM between 14 0/7 and 22 6/7 weeks at UNC Hospitals between 2000 and 2014. Of these, 52 (18.3%) were twin gestations, and 30 of the 52 women met the inclusion criteria (►Fig. 1).

Of the 30 women, 17 (57%) of 30 received prophylactic antibiotics; the remaining 13 (43%) were managed expectantly

### Table 1

<table>
<thead>
<tr>
<th></th>
<th>Received antibiotics</th>
<th>No antibiotics</th>
<th>$p$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Maternal age (y)</strong></td>
<td>29.8 ± 7.6</td>
<td>32.3 ± 5.2</td>
<td>0.30</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>5 (29.4)</td>
<td>5 (38.5)</td>
<td>0.76</td>
</tr>
<tr>
<td>White</td>
<td>9 (52.9)</td>
<td>8 (61.5)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>1 (5.9)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>2 (11.8)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Insurance (private)</strong></td>
<td>10 (58.8)</td>
<td>7 (53.9)</td>
<td>0.13</td>
</tr>
<tr>
<td><strong>Prior preterm birth</strong></td>
<td>3 (17.7)</td>
<td>4 (30.8)</td>
<td>0.67</td>
</tr>
<tr>
<td><strong>Primigravid</strong></td>
<td>5 (29.4)</td>
<td>6 (46.2)</td>
<td>0.45</td>
</tr>
<tr>
<td><strong>Tobacco use</strong></td>
<td>3 (17.6)</td>
<td>1 (7.7)</td>
<td>0.61</td>
</tr>
<tr>
<td><strong>Chorionicty</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monochorionic</td>
<td>5 (29.4)</td>
<td>2 (15.4)</td>
<td>0.43</td>
</tr>
<tr>
<td>Dichorionic</td>
<td>12 (70.6)</td>
<td>11 (84.6)</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2

<table>
<thead>
<tr>
<th></th>
<th>Received antibiotics</th>
<th>No antibiotics</th>
<th>$p$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Median PPROM gestational age, wk, (IQR)</strong></td>
<td>20.0 (19.0, 21.9)</td>
<td>20.3 (17.3, 21.6)</td>
<td>0.45</td>
</tr>
<tr>
<td><strong>ROM &lt; 20 wk gestational age</strong></td>
<td>7 (41)</td>
<td>6 (46)</td>
<td>0.99</td>
</tr>
<tr>
<td>Twin presenting with ROM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Twin A</td>
<td>17 (100)</td>
<td>12 (92.3)</td>
<td>0.43</td>
</tr>
<tr>
<td>Twin B</td>
<td>0</td>
<td>1 (7.8)</td>
<td></td>
</tr>
<tr>
<td>Subsequent ROM of twin B*</td>
<td>2/17 (11.8)</td>
<td>3/12 (25)</td>
<td>0.62</td>
</tr>
<tr>
<td>Cervical dilation at ROM (cm)b</td>
<td>0.4 ± 0.8</td>
<td>1.4 ± 1.6</td>
<td>0.22</td>
</tr>
<tr>
<td>White blood cell count at PPROMa</td>
<td>13.6 (11.5, 14.6)</td>
<td>11.9 (10.6, 16.2)</td>
<td>0.60</td>
</tr>
<tr>
<td>Received at least one dose of antenatal corticosteroids</td>
<td>6 (35.3)</td>
<td>4 (30.8)</td>
<td>&gt; 0.99</td>
</tr>
<tr>
<td>Clinical chorioamnionitis</td>
<td>10 (58.8)</td>
<td>3 (23.1)</td>
<td>0.07</td>
</tr>
<tr>
<td>Birth weight A (g)c</td>
<td>594 ± 318</td>
<td>604 ± 392</td>
<td>0.82</td>
</tr>
<tr>
<td>Birth weight B (g)c</td>
<td>703 ± 493</td>
<td>858 ± 1,000</td>
<td>0.92</td>
</tr>
<tr>
<td>Delivery mode A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cesarean delivery</td>
<td>4 (23.5)</td>
<td>2 (15.4)</td>
<td>0.81</td>
</tr>
<tr>
<td>Vaginal delivery</td>
<td>12 (70.6)</td>
<td>11 (84.6)</td>
<td></td>
</tr>
<tr>
<td>Dilation and evacuation</td>
<td>1 (5.9)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Interval delivery attempted</td>
<td>7 (41.2)</td>
<td>5 (38.5)</td>
<td>&gt; 0.99</td>
</tr>
<tr>
<td>Delivery mode B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cesarean delivery</td>
<td>4 (23.5)</td>
<td>4 (30.8)</td>
<td>&gt; 0.99</td>
</tr>
<tr>
<td>Vaginal delivery</td>
<td>12 (70.6)</td>
<td>9 (69.2)</td>
<td></td>
</tr>
<tr>
<td>Dilation and evacuation</td>
<td>1 (5.9)</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** IQR, interquartile range; PPROM, preterm premature rupture of membranes; ROM, rupture of membranes.

*Data only available from 18 women.

*Data only available from 29 women.

*Data only available from 22 women (missing data from previable deliveries where infant weight not recorded).
without prophylactic antibiotics. Of the 17 women, 13 women received a regimen of ampicillin 2 g intravenous (IV) every 6 (q6) hours and erythromycin 250 mg IV q6 hours × 48 hours, followed by amoxicillin 250 mg orally every 8 (q8) hours and erythromycin 333 mg orally q8 hours × 5 days. One patient each received: Azithromycin only for women with a penicillin allergy, Ampicillin/Sulbactam 1.5 g IV q6 hours × 48 hours, ampicillin 2 g IV q6 hours and erythromycin 250 mg IV q6 hours × 48 hours only, and amoxicillin 250 mg orally q8 hours and erythromycin 333 mg orally q8 hours × 5 days.

The antibiotic-exposed and unexposed groups were similar with regards to demographic and baseline characteristics, including maternal age, race, parity (including the history of preterm birth), and chorionicity (Table 1). The median PPROM gestational age was also similar between antibiotic-exposed and unexposed pregnancies (20.0 vs. 20.3 weeks, p = 0.45) (Table 2). Other PPROM characteristics, including cervical dilation at time of initial evaluation following PPROM and total white blood count at the time of rupture, were also similar between groups (Table 2). Of the 17, 10 (59%) women who receive antibiotics developed clinical chorioamnionitis, compared with 3 (23%) women who did not receive antibiotics (p = 0.07).

There were no significant differences in median gestational age at delivery for either twin A or twin B between two groups (Table 2). Compared with no prophylactic antibiotics, use of antibiotic prophylaxis was not associated with a significant difference in median latency time from ROM to delivery for either twin A or B, though there may be a trend toward longer latency for those who did not receive antibiotics for twin A (Fig. 2A) and twin B (Fig. 2B).

Of the 30 women, 13 (43%) women had maternal morbidity, 7 (41%) who received antibiotics and 6 (42%) who did not receive antibiotics, p < 0.99. Two women developed sepsis before delivery, one in each group. Six women received a transfusion of at least one unit of packed red blood cells, four in the antibiotic group and two in the no-antibiotic group. Endometritis occurred in two women who received antibiotics and one who did not. The acute renal injury occurred in one woman who received antibiotics, and one woman who did not get antibiotics had a pulmonary embolism. Finally, there were no differences in perinatal mortality, neonatal morbidity, or maternal morbidity (Table 3).

Discussion

In this study, use of prophylactic antibiotics in the expectant management of previable PROM in twins did not prolong pregnancy compared with no antibiotics. Maternal morbidity was high, regardless of antibiotic use, which should be considered when counseling women with previable PROM in twins. The majority (57%) of women who elected to continue pregnancy received prophylactic antibiotics, despite data suggesting benefit or lack of harm.

Our findings should be considered in the context of previously reported data. There are some studies that suggest that the use of prophylactic antibiotics given in previable PROM in singletons may improve neonatal outcomes and other which describe the uses of antibiotics without specifically assessing the impact. In one study of 28 singleton pregnancies with previable PPROM, Xiao et al reported a significant neonatal survival difference (51 vs. 0%) following prophylactic antibiotic use, though this was a retrospective study and antibiotics were given at clinician discretion. Others have reported a decreased frequency of chorioamnionitis with the use of antibiotics for periviable PPROM in singletons.

Unfortunately, there is little data on the use of prophylactic antibiotics for PROM in twins. The ORACLE trial of antibiotics in PROM included 450 twins, and found no differences in delivery at 48 hours or 7 days, neonatal death, or major neonatal morbidities compared with no antibiotics. However, the number of twins with ROM at < 24 weeks was not reported thus we cannot generalize this data to the previable twin PROM population. Limited data suggest that while singletons with previable PPROM have improved outcomes
in an era of modern neonatal medicine, with survival in the range of 38 to 56% (but major morbidity in surviving neonates ranges from 52 to 73%), though it is unclear if these improvements may be extrapolated to twin gestations. Wong et al examined the outcomes of 23 multifetal pregnancies complicated by PPROM < 26 weeks’ gestation and found 43% of twins survived, but only 17% survived without significant neonatal morbidity.5 It is, therefore, uncertain whether the use of prophylactic antibiotics in singleton pregnancies complicated by previable PPROM (a clinical problem to which there is no consensus, but more data than for twins) can be appropriately extrapolated to twin gestations.

The physiology of twins is different from singletons and thus interventions may not be applicable between these groups. For example, 17-hydroxyprogesterone for preterm birth (PTB) prevention is effective in singletons, but not twins in reducing recurrent PTB risk.20 The etiology of PROM may vary between twins and singletons, and thus prophylactic antibiotics may not be effective in twin previable PROM. Though not statistically significant, the trend toward longer latency in women who did not receive antibiotics, and the increased chorioamnionitis rate who did receive antibiotics, is concerning for the potential harm of prophylactic antibiotics in previable twin PROM. This study highlights the need for a differential clinical approach to twins compared with singletons.

Our study has limitations. As with any retrospective analysis, the study is subject to bias. The small sample size limits statistical power and our ability to assess the impact of certain variables such as prior preterm delivery. The high rate of perinatal mortality in the setting of twin PROM at < 24 weeks limits our evaluation of prophylactic antibiotics on neonatal morbidities. Our small sample also prevents evaluation of prophylactic antibiotic use at different gestational ages. Additionally, one-third of our patients received an alternative antibiotic regimen, these varied in medication, dosage, and duration. This variation may have also contributed to the findings. The mean gestational age at PPROM was 20 weeks’ gestation, thus latency of at least 3 to 4 weeks would be necessary to demonstrate impact on survival. In addition, several days of latency would be more clinically significant at a later gestational age, as there are significant survival differences when comparing PPROM at < 22 weeks with > 22 weeks.13,16,17 It is also possible that interventions that impact latency in PPROM may be gestational age dependent. Finally, we do not have long-term outcomes data to examine the true effect of antibiotics on surviving infants. A prospective multicenter trial specifically enrolling twins with previable PROM might help to clarify how these patients should be counseled and managed.

The management of twins with previable PPROM is widely debated with variability in clinical practice. Currently, there is no evidence for or against the use of antibiotics in previable PPROM for twin pregnancy. The Society for Maternal Fetal Medicine and American Congress of Obstetrics and Gynecology suggest consideration of latency antibiotics for previable PPROM from 20 to 24 weeks,11,21 Though we were underpowered to show a difference, our findings of no benefit with prophylactic antibiotic use in previable twin PROM and high rates of maternal morbidity, reinforce the importance of active counseling for women and families in this position.

Table 3 Neonatal data for infants born from multiple gestation after previable PPROM (n = 30, 2000–2015)

<table>
<thead>
<tr>
<th></th>
<th>Received antibiotics n = 17 (%)</th>
<th>No antibiotics n = 13 (%)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median latency A, wk, (IQR)</td>
<td>0.8 (0.6, 2)</td>
<td>2.4 (0.5, 4.6)</td>
<td>0.21</td>
</tr>
<tr>
<td>Median latency B, wk, (IQR)</td>
<td>1.2 (0.6, 4.3)</td>
<td>2.9 (0.9, 6.6)</td>
<td>0.25</td>
</tr>
<tr>
<td>Perinatal mortality (A)</td>
<td>13 (76.5)</td>
<td>10 (76.9)</td>
<td>&gt; 0.99</td>
</tr>
<tr>
<td>Perinatal mortality (B)</td>
<td>11 (64.7)</td>
<td>10 (76.9)</td>
<td>0.38</td>
</tr>
<tr>
<td>Median delivery gestational age A, (IQR)</td>
<td>22.7 (18.8, 23.6)</td>
<td>23 (21.9, 23.4)</td>
<td>0.65</td>
</tr>
<tr>
<td>Median delivery gestational age B, (IQR)</td>
<td>23.0 (20.4, 23.7)</td>
<td>23.6 (22.6, 25.0)</td>
<td>0.44</td>
</tr>
<tr>
<td>Maternal morbiditya</td>
<td>7 (41.2)</td>
<td>6 (46.2)</td>
<td>&gt; 0.99</td>
</tr>
<tr>
<td>Neonatal morbidityb (A)</td>
<td>2/4</td>
<td>1/3</td>
<td>&gt; 0.99</td>
</tr>
<tr>
<td>Neonatal morbidityb (B)</td>
<td>1/6</td>
<td>1/3</td>
<td>&gt; 0.99</td>
</tr>
<tr>
<td>Median delivery interval, wk, A to B, (IQR)</td>
<td>0 (0, 0.2)</td>
<td>0.1 (0, 0.4)</td>
<td>0.21</td>
</tr>
</tbody>
</table>

Abbreviations: IQR, interquartile range; PPROM, preterm premature rupture of membranes.

a Includes: Intensive care unit admission, sepsis, acute renal injury, blood transfusion, endometritis, hysterectomy, deep vein thrombosis, pulmonary embolism, and readmission.

b Includes: Necrotizing enterocolitis, grade 3 or 4 intraventricular hemorrhage, bronchopulmonary dysplasia, pulmonary hypoplasia, and sepsis.

Source
This study was performed at the University of North Carolina, Chapel Hill, NC.

Conflict of Interest
The authors report no conflict of interest.
Note
These data were presented as a poster at the Infectious Disease Society of Obstetrics and Gynecology; August 6–8, 2015, Portland, OR.

Acknowledgment
None.

References